Low‐dose gemcitabine plus nab‐paclitaxel versus standard‐dose gemcitabine plus nab‐paclitaxel in elderly patients with metastatic pancreatic cancer: A randomized Phase II trial

BACKGROUND AND AIM: A multicenter, open‐label randomized Phase II trial was conducted to determine whether low‐dose gemcitabine plus nab‐paclitaxel (GnP) could improve tolerability and show equivalent efficacy to the standard‐dose GnP for elderly patients with metastatic pancreatic cancer. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Kamata, Ken, Imai, Hajime, Matsumoto, Hisakazu, Yamashita, Yukitaka, Kato, Takao, Nishi, Katsuhisa, Omoto, Shunsuke, Minaga, Kosuke, Yamao, Kentaro, Hyodo, Tomoko, Im, Sung‐Woon, Hara, Akane, Yoshikawa, Tomoe, Ishikawa, Rei, Okamoto, Ayana, Yamazaki, Tomohiro, Nakai, Atsushi, Ueshima, Kazuomi, Chiba, Yasutaka, Takenaka, Mamoru, Watanabe, Tomohiro, Kitano, Masayuki, Kudo, Masatoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Publishing Asia Pty Ltd 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10517437/
https://www.ncbi.nlm.nih.gov/pubmed/37744711
http://dx.doi.org/10.1002/jgh3.12966

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10517437/
https://www.ncbi.nlm.nih.gov/pubmed/37744711
http://dx.doi.org/10.1002/jgh3.12966

Ejemplares similares